ACP5 and osteoporosis: No significant differences in TRACP5b or BMD were found across AS treatment groups.<h4>Conclusion</h4>Serum TRACP5b may serve as a supplementary marker of osteoclast activity in AS and shows moderate diagnostic value for secondary osteoporosis, with levels more related to age and disease activity than BMD.